CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 26 enrolled
Drug / intervention
Interleukin-2 (aldesleukin).drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02200445
NCT02200445Phase 1Completed
CompareCT.gov

A Phase I Study of Low Dose Subcutaneous Interleukin-2 (IL-2) For The Treatment of Ulcerative Colitis.

Scott B. Snapper, MD PHD·interventional·Posted Jul 25, 2014·Updated Jun 15, 2023

In Brief

A Phase 1 clinical trial evaluating Interleukin-2 (aldesleukin). for Ulcerative Colitis. Completed, enrolled 26 participants across 2 sites.

Detailed Summary

The purpose of this study is to determine the safety and maximum effective dose (MED) of Interleukin-2 in subjects with moderate-to-severe ulcerative colitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 25, 2014
Enrollment StartFeb 1, 2015
Primary CompletionOct 1, 2020
Study CompletionMar 1, 2021
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 11.9 years ago

Interventions

Interleukin-2 (aldesleukin).drug

Description of intervention is covered in "Arm", above.